Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFNα and autologous IL-2-activated lymphocytes)

Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer

1987 • 1,224 citations

Treatment of 283 Consecutive Patients With Metastatic Melanoma or Renal Cell Cancer Using High-Dose Bolus Interleukin 2

1994 • 1,070 citations

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.

1989 • 383 citations

Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry

1990 • 268 citations

Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.

1988 • 197 citations

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

1988 • 159 citations

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2

1992 • 157 citations

Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.

1988 • 153 citations

In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.

1987 • 119 citations

Repetitive Weekly Cycles of Interleukin-2. II. Clinical and Immunologic Effects of Dose, Schedule, and Addition of Indomethacin

1988 • 110 citations

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study.

1989 • 96 citations

Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor.

1990 • 91 citations

Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.

1988 • 80 citations

Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment.

1990 • 75 citations

Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells.

1989 • 72 citations

Recombinant interleukin-2 in metastatic renal cell carcinoma—A European multicentre phase II study

1991 • 54 citations

In vivo production of interleukin-5, granulocyte-macrophage colony- stimulating factor, macrophages colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients [see comments]

1991 • 50 citations

Rapid Cytokine Release in Cancer Patients Treated with Interleukin-2

1992 • 40 citations

alpha-Interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients.

1991 • 37 citations

Expansion of Peripheral Blood Natural Killer Cells Correlates with Clinical Outcome in Cancer Patients Receiving Recombinant Subcutaneous lnterleukin-2 and Interferon-α-2

1993 • 34 citations

Production of tumor necrosis factor α and interferon γ in interleukin-2-treated melanoma patients: Correlation with clinical toxicity

1991 • 32 citations

Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma

1991 • 22 citations

Evaluation of natural killer and lymphokine-activated killer (LAK) cell activity in vivo in patients treated with high-dose interleukin-2 and adoptive transfer of autologous LAK cells

1989 • 18 citations

Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. phenotypic and functional analysis of the peripheral blood mononuclear cells

1990 • 17 citations

Quantification of fluorescence properties of lymphocytes in peripheral blood mononuclear cell suspensions using a latent class model

1993 • 16 citations

Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2

1993 • 13 citations

[Analysis of changes in serum levels of TNF, IL-1 and IL-6 during administration of IL-2. Correlation with clinical response to treatment].

1992 • 8 citations

Metastatic renal‐cell carcinoma patients treated with interleukin 2 or interleukin 2 plus interferon γ: Immunological monitoring

1994 • 7 citations